CRC Research Update — August 23, 2026
Today's colorectal cancer research highlights
ras
A collection of 50 issues
Study compares biologic agents in liver-limited RAS wild-type disease
Skip to content
The CRC Digest
▸ TREATMENT
Study compares biologic agents in liver-limited RAS wild-type disease
A retrospective analysis of 241 patients with RAS wild-type metastatic colorectal cancer confined to the liver compared outcomes among patients treated with first-line chemotherapy plus panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective
Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer
In a study of 1,391 patients, those with persistent or acquired RAS and BRAF mutations in ctDNA had significantly worse overall survival than patients who maintained wild-type status, suggesting liquid biopsy monitoring
CRC Research Update — August 22, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 19, 2026
Today's colorectal cancer research highlights
FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC
A multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist)
This content is informational only and does not
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
Skip to content
The CRC Digest
▸ TREATMENT
Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases
A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients
CRC Research Update — July 27, 2026
Today's colorectal cancer research highlights
Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC
A single-center randomized trial evaluated cetuximab plus irinotecan rechallenge versus regorafenib in RAS wild-type, microsatellite-stable metastatic colorectal cancer patients who had previously responded to then progressed off cetuximab, with progression-free survival as the
Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer
Skip to content
The CRC Digest
Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer
Review outlines next-generation precision approaches for microsatellite-stable tumors, including antibody-drug conjugates, bispecific antibodies, DNA damage response targeting, and tumor microenvironment-directed therapies. (ESMO Open)
This content is informational only and does not constitute medical